Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients

This is a phase I/II, multicenter study to assess the efficacy and safety of IM19 CAR-T cells in adult with R/R Non-Hodgkins Lymphoma in China.

Trial Details

NCT ID
NCT04440436
Phase
PHASE1 / PHASE2
Sponsor
Beijing Immunochina Medical Science & Technology Co., Ltd.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • IM19 CAR-T Cells
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Subjects with relapsed or refractory invasive non-Hodgkin's lymphoma, confirmed by CD19 positive cytology or histology, specific types.
  • CD20 positive patients undergo corresponding targeted therapy.
  • Patients must have evaluable evidence of disease (according to Lugano 2014 standards).
  • ≥ 18 years old.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →